Stella Plevan, PhD
- RESEARCH PROFESSOR | Psychiatry
Research Topics:
Addiction, Brain, Epigenetics, Gene Expressions, Molecular Biology, Neurobiology, RNA Splicing & Processing, Receptors, Schizophrenia
Dr. Dracheva's research centers on the neurobiology and neurochemistry of the brain in health and in mental illness. She applies a variety of molecular techniques to the study of postmortem human brain tissue and animal models. Primary areas of interest include the role of epigenetic (specifically mRNA editing) and genetic (primarily gene expression) mechanisms with a focus on psychiatric phenomena (e.g. suicide, drug addiction, and schizophrenia).
Multi-Disciplinary Training Area
Neuroscience [NEU]Education
PhD, Moscow State University
Research
Specific Clinical/Research Interest:
1. Role of Serotonin 2C Receptor mRNA Editing in Psychiatric Conditions (Suicide, Drug Addiction) 2. Molecular Abnormalities in the Brain of Schizophrenia Patients
Current Students: Rebecca Lyddon
Research Personnel: Kevin Wong, Nayna Patel
My research interests center around the neurobiology and the neurochemistry of several psychiatric conditions including suicide and drug addiction. Specifically, we are investigating the role of serotonin 2C receptor (5-HT2CR) heterogeneity in these pathological states. The 5-HT2CR is encoded by a single gene (HTR2C) but it is expressed as numerous isoforms in brain. One of the sources of the receptor diversity is an editing of its mRNA by hydrolytic deamination that involves conversion of adenosine to inosine. Editing of the 5-HT2CR mRNA takes place at five closely spaced adenosines of the HTR2C mRNA located within a sequence encoding the putative second intracellular domain of the protein -- a region thought to be of general importance for G protein coupling. Because inosines are read as guanosines by the cell's translational machinery, the editing can alter the coding potential of three triplet codons and allows for the generation of 24 different protein isoforms wh! ich vary significantly in their agonist-induced and constitutive activity. In rodent and human brain, a mixture of differently edited and non-edited 5-HT2CR mRNAs has been reported. 5-HT2CR and suicide: Results from a large number of studies have implied that a predisposition of people to suicidal behavior is strongly associated with both psychiatric disease and impaired serotonergic function. The serotonergic involvement with suicide appears to be equally strong, regardless of the associated psychiatric disorder. Therefore, brain serotonergic abnormalities may constitute a common basis for suicidal behavior irrespective of the underlying psychiatric illness. The precise nature of serotonergic defects in suicide remains elusive, however. The 5-HT2CR is a plausible candidate which might contribute to suicidal behavior because it has been shown to be widely distributed in the central nervous system and is thought to play an important role in regulating mood and affect. We are currently investigating whether the editing of 5-HT2CR is altered in the victims of suicide compared to people who died by other causes. 5-HT2CR and drug addiction: A large body of evidence supports the hypothesis that 5HT2CRs that are expressed in the ventral tegmental area (VTA) modulate the basal activity of the dopamine (DA) midbrain neurons through the enhancement of the GABAergic inhibitory neurotransmission, and subsequently, control the rewarding effects of psychostimulants and other drugs of abuse (e.g. ethanol and nicotine). Thus, it is plausible that differences in 5-HT2CR function in VTA influence individual differences in sensitivity to drugs of abuse. In our future studies we are planning to investigate whether an individual's repertoire of the 5-HT2CR isoforms may underlie phenotypic differences in responsivity to drugs of abuse and perhaps predisposition to addiction in rodents and humans.
Dracheva S, Byne WM, Chin B, Haroutunian V. Ionotropic glutamate receptors mRNA expression in the human thalamus: absence of change in schizophrenia. Brain Res 2008; 1214: 23-34.
Dracheva S, Chin B, Haroutunian V. Altered serotonin 2C receptor RNA splicing in suicide: association with editing. Neuroreport 2008; 19: 379-382.
Dracheva S, Patel N, Woo DA, Marcus SM, Siever LJ, Haroutunian V. Increased serotonin 2C receptor mRNA editing: A possible risk factor for suicide. Mol Psychiatry 2007 Sep 11; Epub ahead of print.
Byne WM, Dracheva S, Chin B, Schmeidler , Davis KL, Haroutunian V. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte specific genes in individual thalamic nuclei. Schizophr Res 2008; 98: 118-128.
Haroutunian V, Katsel P, Dracheva S, Stewart DG, Davis KL. Variations in oligodendrocyte-related gene expression across multiple cortical regions: implications for the pathophysiology of schizophrenia. Int J Neuropsychopharmacol 2007; 10: 565-573.
Haroutunian V, Katsel P, Dracheva S, Davis KL. The human homolog of QKI gene affected in the severe dysmyelination . Am J Psychiatry 2006; 163: 1834-1837.
Lauriat TL, Dracheva S, Kremerskothen J, Duning K, Haroutunian V, Buxbaum JD, Hyde TM, Kleinman JE, McInnes LA. Characterization of KIAA0513, a novel signaling molecule that interacts with modulators of neuroplasticity, apoptosis, and the cytoskeleton. Brain Res 2006; 1121: 1-11.
Lauriat TL, Dracheva S, Chin B, Schmeidler J, McInnes LA, Haroutunian V. Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience 2006; 137: 843-851.
Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. Myelin-associated mRNA and protein expression deficits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 2006; 21: 531-540.
Dracheva S, McGurk SR, Haroutunian V. AMPA receptors and AMPA receptor binding proteins expression in DLPFC of elderly schizophrenics. J Neurosci Res 2005; 79: 868-878.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Plevan did not report having any of the following types of financial relationships with industry during 2017 and/or 2018: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.